Brief: Spago Nanomedical Appoints Lead Compound In The Tumorad-Project

Spago Nanomedical AB (publ)

09/01/2020 08:09

Jan 9 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.TE :
    * LEAD COMPOUND APPOINTED IN THE TUMORAD® -PROJECT
    * HAS APPOINTED LEAD COMPOUND IN TUMORAD® -PROJECT AND IS
NOW
PROCEEDING DEVELOPMENT INTO PRE-CLINICAL PROOF-OF-CONCEPT
VALIDATION IN TUMOR MODELS
    * NOMINATION OF LEAD COMPOUND IS AN IMPORTANT STEP MARKING
THAT WE
NOW HOLD A MATERIAL THAT FULFILLS OUR STRICT REQUIREMENTS ON
PHARMACOKINETIC AND CHEMICAL PROPERTIES FOR SELECTIVE
ACCUMULATION IN SOLID TUMORS, AS WELL AS CLINICAL USE
    * IMMEDIATE AIM IS TO INITIATE PRECLINICAL PROOF OF CONCEPT
STUDIES IN SUITABLE TUMOR MODELS
    * DESIGN OF LEAD COMPOUND PARTICLE ALSO OPENS FURTHER
POSSIBILITIES TO INCREASE PATENT PROTECTION FOR TUMORAD®

Source text for Eikon:  ID:nWkr8hz9Qw 
Further company coverage:  SPAGO.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))